Related Experiment Video
Updated: Mar 15, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder
Jingjing Pan1, Xu Li2, Wenjing Wu1
1Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Abstract:
Chemoresistance constitutes the major failing of clinical therapy for bladder cancer. However, the molecular mechanisms involved in the chemoresistance of bladder cancer are unclear. Long non-coding RNAs (lncRNAs) have been implicated in chemotherapeutic drug resistance. Urothelial Cancer Associated 1 (UCA1), an lncRNA, is reportedly upregulated in human bladder carcinoma and promotes cancer cell proliferation, migration, invasion, and drug resistance. In the present study, knockdown of UCA1 decreased chemosensitivity to cisplatin/gemcitabine by suppressing cell proliferation and inducing apoptosis, while overexpression of UCA1 increased chemosensitivity in bladder cancer cells. Moreover, UCA1 activated transcription factor CREB which led to miR-196a-5p expression by binding with its promoter. miR-196a-5p induction is involved in UCA1 inhibition of apoptosis induced by cisplatin/gemcitabine via targeting p27Kip1. These results provide a novel UCA1-CREB-miR-196a-5p paradigm to explain in part how UCA1 functions in cisplatin/gemcitabine resistance, and suggest that UCA1 may be a potential therapeutic target for chemotherapy in bladder cancer.
Insights
Chemoresistance in bladder cancer is a major challenge. This study reveals that Urothelial Cancer Associated 1 (UCA1) long non-coding RNA promotes chemoresistance by activating CREB and miR-196a-5p, suggesting UCA1 as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Chemoresistance is a primary obstacle in bladder cancer treatment, with underlying molecular mechanisms remaining largely unknown.
- Long non-coding RNAs (lncRNAs) are increasingly recognized for their role in modulating cellular responses to chemotherapy.
- Urothelial Cancer Associated 1 (UCA1), a lncRNA, is upregulated in bladder cancer and linked to tumor progression and drug resistance.
Purpose of the Study:
- To elucidate the role of Urothelial Cancer Associated 1 (UCA1) in chemoresistance to cisplatin and gemcitabine in bladder cancer.
- To investigate the molecular pathway through which UCA1 influences chemosensitivity.
- To assess the potential of UCA1 as a therapeutic target for overcoming chemoresistance in bladder cancer.
Main Methods:
- Investigated the effect of UCA1 knockdown and overexpression on bladder cancer cell sensitivity to cisplatin and gemcitabine.
- Analyzed UCA1's impact on cell proliferation and apoptosis.
- Explored the regulatory relationship between UCA1, CREB, miR-196a-5p, and p27Kip1 using molecular biology techniques.
Main Results:
- Knockdown of UCA1 reduced chemosensitivity by suppressing proliferation and inducing apoptosis.
- Overexpression of UCA1 enhanced chemosensitivity in bladder cancer cells.
- UCA1 was found to activate CREB, leading to miR-196a-5p expression, which in turn targets p27Kip1, thereby inhibiting apoptosis induced by chemotherapy.
Conclusions:
- A novel UCA1-CREB-miR-196a-5p signaling axis partially explains UCA1's function in cisplatin/gemcitabine resistance.
- UCA1 plays a significant role in conferring chemoresistance in bladder cancer.
- UCA1 represents a promising therapeutic target for improving chemotherapy efficacy in bladder cancer patients.
Related Concept Videos
lncRNA - Long Non-coding RNAs
MicroRNAs
MicroRNAs
Treatment Resistant Cancers
Induced Pluripotent Stem Cells
Somatic...
piRNA - Piwi-interacting RNAs
